KRAS G12C Inhibitor

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors*

NCT04956640 show modal icon
Key Inclusion Criteria
  • Measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
  • Evidence of KRAS G12C mutation in tumor tissue or circulating tumor DNA
  • Histological or a cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and meet cohort-specific criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate organ function
  • Discontinued all previous treatments for cancer with resolution of any significant ongoing adverse events (AEs), except in certain scenarios
  • Able to swallow capsules/tablets
  • Agree and adhere to contraceptive use, if applicable
  • For some parts of the study (eg, one of the two arms with olomorasib plus pembrolizumab and the arm of olomorasib plus pembrolizumab, pemetrexed, and platinum therapy), histologically or cytologically confirmed stage IIIB-IIIC or stage IV NSCLC that is previously untreated in the advanced/metastatic setting and not suitable for curative intent radical surgery or radiation therapy. Previously untreated patients who received adjuvant and neoadjuvant therapy are eligible if the last dose of the systemic treatment was completed at least 6 months prior to enrollment. For untreated patients in the arm with olomorasib plus pembrolizumab noted above, a single cycle of pembrolizumab may be initiated within 21 days prior to enrollment. For untreated patients in the arm of olomorasib plus pembrolizumab, pemetrexed, and platinum therapy, a single cycle of any or all of the drugs other than olomorasib may be initiated within 21 days prior to enrollment. Start of study treatment may be delayed to allow sufficient time for recovery from treatment-related toxicity
  • For one part of the study, participants must have received at least one prior oxaliplatin- or irinotecan-containing regimen for advanced or metastatic colorectal cancer (CRC)
Key Exclusion Criteria
  • Disease suitable for local therapy administered with curative intent
  • Active, ongoing, or untreated infection
  • Serious preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study
  • Serious cardiac conditions
  • A second active primary malignancy or have been diagnosed and/or treated for an additional malignancy within 3 years prior to enrollment
  • Symptomatic central nervous system (CNS) malignancy or metastasis and/or carcinomatous meningitis. Patients with treated CNS metastases are eligible for this study if their disease is asymptomatic, radiographically stable for at least 30 days, and they do not require treatment with steroids in the 2-week period prior to study treatment. This only applies to some parts of the study
  • Prior treatment with any KRAS G12C small molecule inhibitor, except in certain scenarios where such prior therapy is allowed as per protocol
  • The following patients will be excluded from some parts of the study:
    • Experienced certain serious side effects with prior immunotherapy
    • Have an active autoimmune disease that has required systemic anti-autoimmune treatment in the past 2 years
    • Have received a live vaccine within 30 days prior to the first dose of study drug
  • Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial through 180 days after the last dose of study medication
  • Known allergic reaction against any of the components of the study treatments
This clinical trial is being conducted globally.
Olomorasib is administered PO.
Pembrolizumab is administered intravenously (IV).
Prior KRAS G12C inhibitor allowed.
Pemetrexed is administered IV.
Cisplatin is administered IV.
Carboplatin is administered IV.
Cetuximab is administered IV.
For information on trial enrollment, locations, and more, call 1-800-545-5979.